Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma

A multicentric phase II study of the Southern Italy Oncology Group (GOIM)

Giuseppe Colucci, Evaristo Maiello, Vittorio Gebbia, Rosaria Alba Cifarelli, Maria Biglietto, Antonio Pedicini, Ernesto Durini, Francesco Giuliani, Nicolò Gebbia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In our previous randomized trial of advanced gastric cancer patients, the addition of epirubicin (EPI) to 5-fluorouracil (FU) with folinic acid (FA) resulted in an improved response rate and survival in the responder patients. Preclinical studies also showed an enhancement of FU and anthracyclines with interferon. To evaluate the possibility of human lymphoblastoid interferon (IFN) to enhance the therapeutic activity of the FA-FU + EPI combination regimen, 39 advanced gastric cancer patients received: FU at 375 mg/m 2 i.v. immediately after FA (I-isomer form) at 100 mg/m 2 i.v. for 5 consecutive days; EPI at 60 mg/m 2 i.v. on day 1, and IFN 3 MU s.c. for 7 consecutive days, starting 2 days before the FA-FU administration. Thirty-seven patients were evaluable for response and toxicity. Twelve partial responses were observed with an overall response rate of 32% (95% CI, 17-48%). The median response duration was 6 months, and the median survival time was 8 months. Toxicity was mild and no grade 4 side effects or treatment-related deaths were observed. However, the addition of IFN to the FA-FU + EPI regimen did not improve response, duration of response or survival.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalOncology
Volume53
Issue number4
Publication statusPublished - Jul 1996

Fingerprint

Leucovorin
Interferon-alpha
Fluorouracil
Italy
Stomach
Epirubicin
Carcinoma
Interferons
Stomach Neoplasms
Survival
Anthracyclines
Survival Rate
Therapeutics

Keywords

  • Fluorouracil
  • Folinic acid
  • Gastric carcinoma
  • Interferon

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma : A multicentric phase II study of the Southern Italy Oncology Group (GOIM). / Colucci, Giuseppe; Maiello, Evaristo; Gebbia, Vittorio; Cifarelli, Rosaria Alba; Biglietto, Maria; Pedicini, Antonio; Durini, Ernesto; Giuliani, Francesco; Gebbia, Nicolò.

In: Oncology, Vol. 53, No. 4, 07.1996, p. 269-274.

Research output: Contribution to journalArticle

Colucci, Giuseppe ; Maiello, Evaristo ; Gebbia, Vittorio ; Cifarelli, Rosaria Alba ; Biglietto, Maria ; Pedicini, Antonio ; Durini, Ernesto ; Giuliani, Francesco ; Gebbia, Nicolò. / Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma : A multicentric phase II study of the Southern Italy Oncology Group (GOIM). In: Oncology. 1996 ; Vol. 53, No. 4. pp. 269-274.
@article{cf417b0fdb6e45409d717a0427173d94,
title = "Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma: A multicentric phase II study of the Southern Italy Oncology Group (GOIM)",
abstract = "In our previous randomized trial of advanced gastric cancer patients, the addition of epirubicin (EPI) to 5-fluorouracil (FU) with folinic acid (FA) resulted in an improved response rate and survival in the responder patients. Preclinical studies also showed an enhancement of FU and anthracyclines with interferon. To evaluate the possibility of human lymphoblastoid interferon (IFN) to enhance the therapeutic activity of the FA-FU + EPI combination regimen, 39 advanced gastric cancer patients received: FU at 375 mg/m 2 i.v. immediately after FA (I-isomer form) at 100 mg/m 2 i.v. for 5 consecutive days; EPI at 60 mg/m 2 i.v. on day 1, and IFN 3 MU s.c. for 7 consecutive days, starting 2 days before the FA-FU administration. Thirty-seven patients were evaluable for response and toxicity. Twelve partial responses were observed with an overall response rate of 32{\%} (95{\%} CI, 17-48{\%}). The median response duration was 6 months, and the median survival time was 8 months. Toxicity was mild and no grade 4 side effects or treatment-related deaths were observed. However, the addition of IFN to the FA-FU + EPI regimen did not improve response, duration of response or survival.",
keywords = "Fluorouracil, Folinic acid, Gastric carcinoma, Interferon",
author = "Giuseppe Colucci and Evaristo Maiello and Vittorio Gebbia and Cifarelli, {Rosaria Alba} and Maria Biglietto and Antonio Pedicini and Ernesto Durini and Francesco Giuliani and Nicol{\`o} Gebbia",
year = "1996",
month = "7",
language = "English",
volume = "53",
pages = "269--274",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma

T2 - A multicentric phase II study of the Southern Italy Oncology Group (GOIM)

AU - Colucci, Giuseppe

AU - Maiello, Evaristo

AU - Gebbia, Vittorio

AU - Cifarelli, Rosaria Alba

AU - Biglietto, Maria

AU - Pedicini, Antonio

AU - Durini, Ernesto

AU - Giuliani, Francesco

AU - Gebbia, Nicolò

PY - 1996/7

Y1 - 1996/7

N2 - In our previous randomized trial of advanced gastric cancer patients, the addition of epirubicin (EPI) to 5-fluorouracil (FU) with folinic acid (FA) resulted in an improved response rate and survival in the responder patients. Preclinical studies also showed an enhancement of FU and anthracyclines with interferon. To evaluate the possibility of human lymphoblastoid interferon (IFN) to enhance the therapeutic activity of the FA-FU + EPI combination regimen, 39 advanced gastric cancer patients received: FU at 375 mg/m 2 i.v. immediately after FA (I-isomer form) at 100 mg/m 2 i.v. for 5 consecutive days; EPI at 60 mg/m 2 i.v. on day 1, and IFN 3 MU s.c. for 7 consecutive days, starting 2 days before the FA-FU administration. Thirty-seven patients were evaluable for response and toxicity. Twelve partial responses were observed with an overall response rate of 32% (95% CI, 17-48%). The median response duration was 6 months, and the median survival time was 8 months. Toxicity was mild and no grade 4 side effects or treatment-related deaths were observed. However, the addition of IFN to the FA-FU + EPI regimen did not improve response, duration of response or survival.

AB - In our previous randomized trial of advanced gastric cancer patients, the addition of epirubicin (EPI) to 5-fluorouracil (FU) with folinic acid (FA) resulted in an improved response rate and survival in the responder patients. Preclinical studies also showed an enhancement of FU and anthracyclines with interferon. To evaluate the possibility of human lymphoblastoid interferon (IFN) to enhance the therapeutic activity of the FA-FU + EPI combination regimen, 39 advanced gastric cancer patients received: FU at 375 mg/m 2 i.v. immediately after FA (I-isomer form) at 100 mg/m 2 i.v. for 5 consecutive days; EPI at 60 mg/m 2 i.v. on day 1, and IFN 3 MU s.c. for 7 consecutive days, starting 2 days before the FA-FU administration. Thirty-seven patients were evaluable for response and toxicity. Twelve partial responses were observed with an overall response rate of 32% (95% CI, 17-48%). The median response duration was 6 months, and the median survival time was 8 months. Toxicity was mild and no grade 4 side effects or treatment-related deaths were observed. However, the addition of IFN to the FA-FU + EPI regimen did not improve response, duration of response or survival.

KW - Fluorouracil

KW - Folinic acid

KW - Gastric carcinoma

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=0030004762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030004762&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 269

EP - 274

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -